Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

ARS Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 14, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ARS PHARMACEUTICALS INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ARS SECURITIES BETWEEN MARCH 9, 2026 AND JUNE 24, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ARS AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX REMINDS ARS PHARMACEUTICALS INC. (SPRY) INVESTORS SEEKING RECOVERY OF THE LEAD PLAINTIFF DEADLINE ON OCTOBER 5, 2026

$26.2 MILLION IN U.S. NEFFY  NET PRODUCT REVENUE IN Q2 2026; TOTAL U.S. EPINEPHRINE MARKET SHARE FOR TYPE 1 ALLERGIES OF 5% AND 8% SHARE WITHIN FIELD-TARGETED ACCOUNTS

ARS PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES, INCLUDING A FOCUSED COMMERCIAL STRATEGY, AND REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SAN DIEGO, CALIFORNIA--(NEWSFILE CORP. - AUGUST 13, 2026) - ROBBINS LLP REMINDS SHAREHOLDERS THAT A SECURITIES CLASS ACTION HAS BEEN FILED ON BEHALF OF ALL INVESTORS WHO PURCHASED OR OTHERWISE ACQUIRED ARS PHARMACEUTICALS INC. (NASDAQ: SPRY) SECURITIES BETWEEN MARCH 9, 2026 AND JUNE 24, 2026 (THE "CLASS PERIOD"). ARS IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF NEFFY FOR NEEDLE-FREE INTRANASAL DELIVERY OF EPINEPHRINE FOR EMERGENCY TREATMENT OF TYPE 1 ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS.

DID YOU LOSE MONEY INVESTING IN ARS PHARMACEUTICALS INC.? ROBBINS LLP URGES INVESTORS WITH SIGNIFICANT LOSSES TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS AGAINST SPRY

PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - AUGUST 13, 2026) - GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON BEHALF OF SHAREHOLDERS OF ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY). WHAT IS THE INVESTIGATION ABOUT?

GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF LONG-TERM SHAREHOLDERS OF ARS PHARMACEUTICALS, INC. (SPRY)

NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 12, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ARS PHARMACEUTICALS INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ARS SECURITIES BETWEEN MARCH 9, 2026 AND JUNE 24, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ARS AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX ENCOURAGES INVESTORS OF ARS PHARMACEUTICALS INC. (SPRY) WHO SUFFERED LOSSES TO CONTACT THE FIRM BEFORE OCTOBER 5, 2026

LOS ANGELES--(BUSINESS WIRE)---- $SPRY--ARS PHARMACEUTICALS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SPRY.

ARS PHARMACEUTICALS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SPRY

LOS ANGELES, AUG. 10, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUPREMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINSTARS PHARMACEUTICALS, INC. ("ARS" OR "THE COMPANY") (NASDAQ: SPRY) VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SPRY DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

ARS PHARMACEUTICALS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - SPRY

NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 7, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ARS PHARMACEUTICALS INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ARS SECURITIES BETWEEN MARCH 9, 2026 AND JUNE 24, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ARS AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX NOTIFIES ARS PHARMACEUTICALS INC. (SPRY) INVESTORS OF AN UPCOMING LEAD PLAINTIFF DEADLINE ON OCTOBER 5, 2026

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF SECURITIES OF ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY) BETWEEN MARCH 9, 2026 AND JUNE 24, 2026 INCLUSIVE (THE CLASS PERIOD). ARS PHARMACEUTICALS IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEGATIONS: ROSEN LAW FIRM IS INVESTIGATING THE ALLEGATIONS TH.

ROSEN LAW FIRM URGES ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY) STOCKHOLDERS WITH LARGE LOSSES TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

SAN DIEGO, AUG. 03, 2026 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 13, 2026, AT 1:30 P.M. PT / 4:30 P.M. ET. DURING THE CALL, DONN CASALE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL OUTLINE THE COMPANY'S UPDATED STRATEGIC PRIORITIES AND REPORT SECOND QUARTER 2026 FINANCIAL RESULTS.

ARS PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST ON AUGUST 13 OUTLINING ITS UPDATED STRATEGIC PRIORITIES AND REPORTING SECOND QUARTER 2026 FINANCIAL RESULTS

NEW YORK, JULY 23, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. - SPRY

NEW YORK, JULY 21, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, JULY 16, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 14, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, JULY 9, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 07, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

RICHARD LOWENTHAL, CHIEF EXECUTIVE OFFICER, TRANSITIONING FOLLOWING MORE THAN A DECADE OF LEADERSHIP SINCE CO-FOUNDING THE COMPANY

ARS PHARMACEUTICALS ANNOUNCES CEO SUCCESSION

NEW YORK--(BUSINESS WIRE)--SHAREHOLDERS WHO HELD ARS PHARMACEUTICALS (NASDAQ: SPRY) STOCK WATCHED THE VALUE DROP MORE THAN 23% IN AFTER-HOURS TRADING ON JUNE 24, 2026, AFTER THE COMPANY DISCLOSED THAT NEFFY RECEIVED NO NEW COMMERCIAL FORMULARY ADDITIONS OR PAYER-COVERAGE DECISIONS IN THE JULY 1, 2026 REVIEW CYCLE. INVESTORS WHO LOST MONEY ON SPRY ARE ENCOURAGED TO SUBMIT THEIR INFORMATION TO DISCUSS THEIR LEGAL RIGHTS. YOU MAY ALSO CONTACT JOSEPH E. LEVI, ESQ. VIA EMAIL AT JLEVI@LEVIKORSINSKY.

SPRY INVESTOR ALERT: LEVI & KORSINSKY INVESTIGATES ARS PHARMACEUTICALS (SPRY) FOR POTENTIAL SECURITIES FRAUD

NEW YORK, JUNE 30, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NO NEW COMMERCIAL FORMULARY ADDITIONS OR COVERAGE DECISIONS ISSUED FOR NEFFY (EPINEPHRINE NASAL SPRAY) IN THE JULY 1, 2026 CYCLE; COMPANY TO CONTINUE PAYER DISCUSSIONS FOR POTENTIAL FUTURE INCLUSION

ARS Pharmaceuticals, Inc.

SPRY

Price

Financial Reports

No items found.

Press Releases

ARS Pharmaceuticals, Inc.

SPRY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SPRY